BillionToOne is a biotechnology company that develops molecular diagnostics for genetic diseases. The company's platform, called the QCT molecular counter, uses a proprietary technology to detect rare mutations in DNA samples. BillionToOne's technology is used in prenatal testing, cancer diagnostics, and other applications. The company was founded in 2016 and is headquartered in San Francisco, California.